MediWound (NASDAQ:MDWD – Get Free Report) and CG Oncology (NASDAQ:CGON – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.
Profitability
This table compares MediWound and CG Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -170.10% | -47.24% | -24.27% |
| CG Oncology | -3,602.68% | -25.20% | -23.98% |
Earnings & Valuation
This table compares MediWound and CG Oncology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediWound | $16.96 million | 9.74 | -$23.88 million | ($1.80) | -7.14 |
| CG Oncology | $6.23 million | 922.12 | -$160.99 million | ($2.69) | -24.09 |
MediWound has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
46.8% of MediWound shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and recommmendations for MediWound and CG Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 1 | 1 | 4 | 0 | 2.50 |
| CG Oncology | 1 | 1 | 8 | 0 | 2.70 |
MediWound presently has a consensus target price of $33.00, indicating a potential upside of 156.83%. CG Oncology has a consensus target price of $87.50, indicating a potential upside of 35.05%. Given MediWound’s higher possible upside, research analysts plainly believe MediWound is more favorable than CG Oncology.
Volatility and Risk
MediWound has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Summary
MediWound beats CG Oncology on 8 of the 14 factors compared between the two stocks.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
About CG Oncology
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
